Open Access Research article

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

Karolina Partheen1*, Kristina Levan1, Lovisa Österberg1, Ingela Claesson1, Karin Sundfeldt2 and György Horvath1

Author Affiliations

1 Department of Oncology, Institute of clinical sciences, University of Gothenburg, Gothenburg, Sweden

2 Department of Obstetrics and Gynecology, Institute of clinical sciences, University of Gothenburg, Gothenburg, Sweden

For all author emails, please log on.

BMC Cancer 2009, 9:336  doi:10.1186/1471-2407-9-336

Published: 23 September 2009

Abstract

Background

The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external validation of the potential biomarkers CLU, ITGB3, CAPG, and PRAME to determine if the expression levels are relevant to use as prognostic factors.

Methods

We analysed the gene expression of CLU, ITGB3, CAPG, and PRAME in 30 advanced staged serous adenocarcinomas with quantitative real-time polymerase chain reaction (QPCR) and the protein levels were analysed in 98 serous adenocarcinomas with western blot for semiquantitative analysis. Statistical differences in mRNA and protein expressions between tumours from survivors and tumours from deceased patients were evaluated using the Mann-Whitney U test.

Results

The gene and protein ITGB3 (Integrin beta 3) were significantly more expressed in tumours from survivors compared to tumours from deceased patients, which is in concordance with our previous results. However, no significant differences were detected for the other three genes or proteins CLU, CAPG, and PRAME.

Conclusion

The loss of ITGB3 expression in tumours from deceased patients and high expression in tumours from survivors could be used as a biomarker for patients with advanced serous tumours.